AOC3 and metabolic dysfunction-associated steatohepatitis: AOC3 inhibition, using anti-AOC3 antibodies, has been shown to reduce inflammatory cell recruitment to the liver in murine hepatic injury models and in vitro cultured active hepatic stellate cells from liver tissue of patients with NASH cirrhosis16.